The American Chemical Society (ACS) will host the 2nd Annual ACS Industry Symposium 14 – 15 December 2017 in Mumbai, India.
The conference theme is “Global Challenges and Recent Advances in Biologics and Biosimilars.” The program will include two days of presentations and panel discussions on healthcare-related challenges, new developments in biologics, immunotherapy, protein design and protein chemistry, as well as aspects of biopharmaceutical development of particular interest to the developing world. The symposium will feature opportunities for discussion during networking sessions and catered meals.
Register now for the symposium. For those who are not yet ACS members, 1 year of membership to the American Chemical Society will be included in the registration fee.View Schedule
Dr. Ranjan Chakrabarti is currently Vice President V.P. at United States Pharmacopoeia at their India office. He has over 20 years of experience in Pharmaceutical and Biopharma industries. Before joining industry, he worked in Academics at SUNY, Buffalo and University of Massachusetts Medical Center and successfully coordinated research projects in Cancer Cell Biology and Diabetes. He has guided several Ph. D. students. Dr. Chakrabarti was leading the Biology Group at Dr. Reddy’s Drug Discovery unit and was involved in discovering several clinical candidates, out licensing deals and leading collaborative projects with MNCs. He has also served at key management position in GVK Biosciences for both Drug Discovery services and collaborative Drug Discovery research. In this role, he has worked with several National and International Pharma and Biopharma companies for discovery and development of both chemical and biological molecules. Dr. Chakrabarti is the Co-Inventor of 32 US Patents; published 52 papers in peer reviewed International Journals and presented 57 lectures in International and National Conferences.
Dr. Virginia W. Cornish graduated summa cum laude from Columbia University with a B.A. in Biochemistry in 1991, where she did undergraduate research with Professor Ronald Breslow. She earned her Ph.D. in Chemistry with Professor Peter Schultz at the University of California at Berkeley and then was a Postdoctoral Fellow in the Biology Department at M.I.T. under the guidance of Professor Robert Sauer. Virginia joined the faculty of the Chemistry Department at Columbia in 1999, where she carries out research at the interface of chemistry and biology, and was promoted to Associate Professor with tenure in 2004 and then Professor in 2007.
Her laboratory brings together modern methods in synthetic chemistry and DNA technology to expand the synthetic capabilities of living cells. Her research has resulted in 59 research publications and several patents and currently is supported by multiple grants from the NIH and NSF. Virginia has been recognized for her research by awards including an NSF Career Award (2000), a Sloan Foundation Fellowship (2003), the Protein Society Irving Sigal Young Investigator Award (2009), and the American Chemical Society Pfizer Award in Enzyme Chemistry (2009).
Dr. Priti Hegde is a Director and Global Franchise Biomarker Lead for cancer immunotherapy franchise at Genentech/Roche. Prior to joining Genentech in 2007, Dr. Hegde led genomics based biomarker activities in Oncology and cardiovascular diseases at GSK.
Dr. Hegde received her postdoctoral training in colorectal cancer genomics at the Institute for Genomic Research (TIGR) in 2000 and her graduate training in Biochemical Pharmacology from SUNY, Buffalo.
Professor Donald Hilvert has been full Professor at the Organic Chemistry Laboratory of ETH Zurich since October 1, 1997. His group is developing general strategies for the design of proteins with customized catalytic properties. The aim is to gain a better understanding of the molecular origins of the catalytic powers of natural enzymes and their selectivity. Beyond that artificial biocatalysts may be useful in research, medicine and industry.
Professor Hilvert was born in 1956 in Cincinnati, Ohio, USA, and obtained his B.A. from Brown University, Rhode Island, in 1978. He earned his Ph.D. from Columbia University, New York, in 1983, with a dissertation under the supervision of Prof. R. Breslow. Following a postdoctoral work with Prof. E.T. Kaiser at Rockefeller University, New York, he joined the Scripps Research Institute as an assistant professor in 1986, where he was named associate professor in 1989 and full professor in 1993. He came to ETH Zurich as full Professor of Organic Chemistry in 1997.
Donald Hilvert was awarded the Alfred P. Sloan Research Fellowship in 1991-93, the Arthur C. Cope Scholar Award of the ACS in 1992, and the Pfizer Award in Enzyme Chemistry in 1994.
Dr. Harish Iyer is a Senior Advisor for Scientific Programs at the Bill and Melinda Gates Foundation. Dr. Iyer previously served as CEO at Hyderabad-based vaccines maker Shantha Biotechnics Ltd., part of Sanofi Aventis Group. He has also worked in global biotech drug makers like Biocon and Biogen Idec.
Dr. Iyer has a Ph.D. in Chemical Engineering from the Rensselaer Polytechnic Institute and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, Madras.
Dr. Krishna Kumar is Robinson Professor of Chemistry, Chairman of the Chemistry Department and Adjunct Professor of Biomedical Engineering at Tufts University. He is a Member of the Cancer Center at the Tufts Medical Center in Boston, USA. His research interests span synthetic organic chemistry, chemical biology, medicinal chemistry, biophysics and cell biology. A recognized expert in peptide therapeutics, he is also a co-founder of several start-up companies.
Dr. Kumar’s contributions to science, and in particular chemistry and medicine, have been recognized widely. He was named a DuPont Young Professor, recognized as one of the top 35 young innovators in the world by MIT Technology Review magazine (TR35) and awarded a Global Indus Technovator award from MITIBC. He is a recipient of the National Science Foundation CAREER award, the Technology award from the Massachusetts Technology Transfer Center and the Excellence in Chemical Sciences award from the Indian Society for Chemistry and Biology. He also was elected a Fellow of the American Association of the Advancement of Science (AAAS). He is a regular consultant to biotech and pharmaceutical companies.
Dr. Sunit Maity completed his Ph.D. from Catholic University, Leuven, Belgium, and prior to that, has spent several years on extensive research in European academic and industry environment.
With a knack for combining academic research with practical knowledge, Dr. Sunit, puts his vast experience in biotechnology industries to use in building a strong organization at Zumutor. His areas of expertise lie in cardiovascular biology and cell line development.
He has also worked with Avesthagen in the capacity of Biosimilar Head. Dr. Sunit is a highly motivated, energetic and proactive individual with 10 years of managerial experience in both upstream and downstream development of biosimilars such as recombinant protein and monoclonal antibodies.
Dr. Dhananjay Patankar, Ph.D. serves as Head of Pharmaceutical and Biopharmaceutical Development at Syngene International Ltd. Dr. Patankar joined Syngene in October 2010 and heads formulation, biologics development and cGMP manufacturing for all biologics (recombinant proteins, antibodies and other macromolecules) as well as drug products (variety of dosage forms for small and large molecules).
He was associated with Intas Biopharmaceuticals Ltd. Ahmedabad, as Chief Operating Officer. He was also associated with the Biotechnology Division of Wockhardt Research Center, Aurangabad as a Senior Scientist and Group Head for product development and manufacturing. Immediately prior to joining Syngene, he led the CMC development of a biosimilar which has received Marketing Authorization in Europe, wherein he directly supervised areas such as process characterization and validation, analytical development and validation, product characterization and comparability and CMC regulatory strategy.
Dr. Patankar served as an industry representative on a National Task Force for establishing regulatory pathway for biosimilars in India. He serves as the Chairman of the Institutional Animal Ethics Committee. He serves as Chair of a US Pharmacopeia Expert Committee for Biologics and Member of US Pharmacopeia Council of Experts. Dr. Patankar did his Postdoctoral Fellowship at the Dept. of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ (USA). He obtained his Ph.D. in 1992 and M.S. in 1989 in Chemical Engineering from University of Utah, Salt Lake City and B.Tech. in Chemical Engineering from Indian Institute of Technology, Bombay in 1986.
Dr. Taslim Saiyed is the Director and COO of C-CAMP, Centre for Cellular and Molecular Platforms. In this role he manages C-CAMP's technology platforms, growth strategies, strategic collaborations for new technology creation, and education and training programmes, as well as the business and innovation accelerator unit. He also oversees the Intellectual Property and Technology Transfer Office at C-CAMP. Prior to joining C-CAMP, he worked as a Scientist with University of California, San Francisco (UCSF) studying neurodegenerative diseases like Parkinson's disease.
Dr. Saiyed's initial training has been in neuroscience where he received his PhD from Max-Planck Institute for Brain Research, Germany and followed up by postdoctoral training at University of California San Francisco (UCSF). At the same time, he also underwent training in management for Biotech and Innovation from QB3 at UCSF, UC Berkeley and UCSC. Dr. Saiyed has been selected as "one of the top-20 young scientists" by Roche in 2004.
Individually, he is actively involved and impassioned for promoting innovation in life science through supporting translation of discoveries to application, entrepreneurship and technology development.
Peter H. Seeberger studied chemistry in Erlangen (Germany) and completed a Ph.D. in biochemistry in Boulder (USA). After performing research at the Sloan-Kettering Cancer Center Research in New York he built an independent research program at MIT where he was promoted to Firmenich Associate Professor of Chemistry with tenure. After six years as Professor at the Swiss Federal Institute of Technology (ETH) Zurich he assumed positions as Director at the Max-Planck Institute for Colloids and Surfaces in Potsdam and Professor at the Free University of Berlin in 2009. In addition he serves as honorary Professor at the University of Potsdam. From 2003-2014 he was Affiliate Professor at the Sanford-Burnham Institute for Medical Research (La Jolla, USA). He is a member of the Max-Planck Society “Senate” and the Berlin-Brandenburg Academy of Sciences “Rat”.
Professor Seeberger’s research on the chemistry and biology of carbohydrates, carbohydrate vaccine development and continuous flow synthesis of drug substances spans a broad range of topics from engineering to immunology and has been documented in over 450 peer-reviewed journal articles, four books, more than 40 patents, over 200 published abstracts and more than 800 invited lectures. This work was recognized with more than 25 international awards from the US (e.g. Arthur C. Cope Young Scholar Award, Horace B. Isbell Award, Claude S. Hudson Award from the American Chemical Society), Germany (e.g. Körber Prize for European Sciences, Wissenschaftspreis des Stifterverbandes), Holland (Havinga Medal), Israel (Honorary Lifetime Member Israel Chemical Society), Japan (Yoshimasa Hirata Gold Medal), Switzerland (“The 100 Most Important Swiss”) and international organizations (Whistler Award 2012, Int. Carboh. Soc.). In 2013 he was elected to the Berlin-Brandenburg Academy of Sciences.
Peter H. Seeberger greatly supports the idea of open access publishing as the Editor-in-Chief of the Beilstein Journal of Organic Chemistry and serves on the editorial advisory boards of many other journals.
Through his work in the area of neglected diseases, Peter Seeberger has become involved in philanthropic causes. He is a co-founder of the Tesfa-Ilg “Hope for Africa” Foundation that aims at improving health care in Ethiopia that recently helped to build a bed-net factory and established an IT training center.
The research in the Seeberger laboratory has given rise to seven successful companies in the USA, Switzerland and Germany.
Dr. Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry, since September 2002. He leads the company’s chemistry department, which carries out research in antibody-drug conjugate technologies, the development of potent drug payloads, novel linker systems, conjugation methodology, mechanism of action studies and the development of glycan-modified antibody structures. Prior to joining Seattle Genetics, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute, and the Dana-Farber Cancer Institute, Harvard Medical School.
Dr. Senter received an A.B. in biochemistry from the University of California, Berkeley, and a Ph.D. in chemistry from the University of Illinois, and did postdoctoral research at the Max Planck Institute of Experimental Medicine in Göttingen, Germany. He is the Senior Editor of Molecular Cancer Therapeutics (AACR) and serves as an Affiliate Professor of Bioengineering at the University of Washington, and of Pharmaceutical Sciences at the University of Southern California. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 150 scientific publications and holds more than 40 patents.
Dr. Molly Shoichet holds the Tier 1 Canada Research Chair in Tissue Engineering and is University Professor of Chemical Engineering & Applied Chemistry, Chemistry and Biomaterials & Biomedical Engineering at the University of Toronto. She is an expert in the study of Polymers for Drug Delivery & Regeneration which are materials that promote healing in the body.
Dr. Shoichet has published over to 480 papers, patents and abstracts and has given over 310 lectures worldwide. She currently leads a laboratory of 25 researchers and has graduated 134 researchers over the past 20 years. She founded two spin-off companies from research in her laboratory.
She is the recipient of many prestigious distinctions and the only person to be a Fellow of Canada's 3 National Academies: Canadian Academy of Sciences of the Royal Society of Canada, Canadian Academy of Engineering, and Canadian Academy of Health Sciences. Dr. Shoichet won the L’Oreal-UNESCO for Women in Science Award for North America in 2015. Dr. Shoichet holds the Order of Ontario, Ontario's highest honour and is a Fellow of the American Association for the Advancement of Science. In 2013, her contributions to Canada's innovation agenda and the advancement of knowledge were recognized with the QEII Diamond Jubilee Award. In 2014, she was given the University of Toronto's highest distinction, University Professor, a distinction held by less than 2% of the faculty.
Rajiv Kumar Tayal holds a Doctorate in Chemical Engineering and Diploma in Project Management. He is a Certified Assessor / Trainer for Laboratory Accreditation Systems, ISO – 9000 Quality Management Systems and ISO – 14000 Environment Management Systems. He has close to 35 years of professional experience in Science, Technology and Innovation space, while directly serving in Industry and Government and closely interfacing with a large number of academic institutions, research laboratories and industry in India. He is a Fellow of the Indian National Academy of Engineering, FNAE and The Institution of Engineers (India), FIE.
He had initially worked in industrial R&D dealing with various facets of technology development and project implementation/management, in real time. He has extensive hands on experience of working with various segments of the overall R&D landscape, which imparts him with a unique skillset in visualizing interconnects and overall integration of R&D value chain from concept to commercialization. In addition to providing technical support to running plant production activities, he had been involved in the development of several processes/technologies for new products which were actually put to real-life implementation.
Until recently, he had been working as an Advisor in the Department of Science & Technology (DST), Government of India, dealing with overall Science & Technology policy framework and several direct interventions through a vast range of schemes and programs related to promotion of scientific research and capacity building. Over the years, he has presided over some of the best and most efficiently managed R&D programs in DST, receiving due acknowledgement and wide acclaim from the research community.
He developed several partnerships and collaborative R&D programs with other S&T agencies, socio-economic ministries and industries in India, including some of the leading US federal agencies like, National Science Foundation (NSF) and National Institute of Health (NIBIB/NIH). He created a unique model to seamlessly connect Indian federal S&T agencies with all the state governments and developed a platform for technology access to fulfill developmental agenda at the grass root level, through a dynamic-interactive Technology Portal as a single point showcase of technologies developed by all the Indian federal S&T agencies.
He is currently leading the bi-national Indo-US Science & Technology Forum (IUSSTF) as its Executive Director. IUSSTF performs a critical role in connecting S&T eco-systems of the US and India through a rich portfolio of networking programs, strategic missions in the areas of energy and biomedical devices, large international collaborative projects and innovation led commercialization of technology. In addition to providing overall leadership to IUSSTF, he personally drives Innovation and Entrepreneurial initiatives for start-ups to translate new ideas into tangible business opportunities.
Matthew Toussant is responsible for building the CAS content collections, provides leadership for new products and content, and leads product capabilities developed for CAS solutions, including SciFinder and STN. His unit is accountable for services CAS provides under the United States Environmental Protection Agency contract in support of the Toxic Substances Control Act. Toussant’s duties as head of CAS content operations date to 1998, and his role with products began in March 2014. He holds B.S., M.S. and Ph.D. degrees from The Ohio State University, specializing in food chemistry and nutritional biochemistry.
Dr. Ming-Wei Wang obtained his medical degree from Shanghai Medical University in 1982. Following a practice as an orthopedic surgeon in Shanghai, he attended UCLA School of Medicine and the Institute of Animal Physiology at Cambridge, UK. He was awarded a Ph.D. in physiology by University of Cambridge in 1989 and started his research career in several USA-based biotechnology companies, including Amylin Pharmaceuticals and Ligand Pharmaceuticals.
He was heavily involved in entrepreneurial activities and co-funded several biopharmaceutical start-up companies in the USA, the UK, China and Hong Kong. Dr. Wang was appointed as a Professor of pharmacology at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), and Executive Deputy Director of the Chinese National Center for Drug Screening in 2001. The WHO/TDR named him as one of the 12 expert members for the Thematic Reference Group on Innovation and Technology, Shanghai Clinical Research Center appointed him as a Senior Advisor on International Business Affairs, and Chinese Academy of Medical Sciences/Peking Union Medical College made him Guest Professor.
Dr. Wang has published more than 170 research papers, received a number of academic awards or social honors from the UK, the USA, Taiwan and China, and obtained 63 international patents. Dr. Wang’s research achievements include the discovery of the first non-peptidic glucagon-like peptide-1 receptor agonist (Boc5), the determination of the 3-D structure of the human glucagon receptor and its conformational states, and the elucidation of the insulinotrophic effect of insulin-like peptide 5 (INSL5) as well as the identification of the oncologic link of GPR160, an orphan G protein-coupled receptor.
Professor Ganapati D. Yadav ranks among the preeminent engineers and academicians in India. He is internationally recognized by many prestigious awards, fellowships and honours for his seminal contributions to education, research, innovation and development of clean and green technologies. He has provided inspiring academic and professional leadership to the Institute of Chemical Technology (ICT), the Indian Institute of Chemical Engineers (IIChE) and Catalysis Society of India, and Maharashtra Academy of Sciences.
His leadership has seen phenomenal growth of the ICT which is rated as the best in chemical sciences and engineering ranked among the top five in the world with several awards such as CHEMTECH Foundation’s Best R and D Institute, Number 1 rank in Chemical Engineering in India and No.4 in the World in research publications. Maharashtra Government’s Elite Institute Status and Centre of Excellence like IITs, IISc, IISERs, No. 1 TEQIP funded institute among 127 during Phase 1 and lead institute in Phase II. The Tata Chemicals AICTE-CII Best Industry Linked Institute award in Chemical Engineering was bestowed recently on ICT for 2012. All departments of the Institute are supported by the DST-FIST and UGC-SAP with 710 doctorates, 450 masters and 1100 UG students. It is recognised as a model for industry-institute collaboration. Several prestigious universities from the USA, UK, Australia, France, Canada and New Zealand, as well as leading industries from across the globe and from India have signed MOUs with the ICT to promote research and development of technologies. He has been responsible for getting munificent donations for the ICT for faculty endowments, student and non-teaching staff support and infrastructure and the institute now has a modern ambiance and facilities on par with the best in India and abroad.
He has received numerous honours and distinctions for his path-breaking contributions to green chemistry and engineering, catalysis science and engineering, chemical reaction engineering, nanotechnology and energy engineering. He has supervised 75 doctoral students and 74 master’s students, and has authored over 300 original research papers in 51 cross-disciplinary international peer-reviewed journals. He also holds 67 patents and has authored 3 books. He has h-index of 41 and i10 index of 145 with over 6200 citations. He is a Fellow of the Indian National Science Academy (INSA) and the National Academy of Sciences, India (NASI), among others. He has been honoured by the Government of India’s Department of Science and Technology with its prestigious Jagdish Chandra Bose National Fellowship and is the only active university faculty member in the state of Maharashtra to be elected as Fellow of The World Academy of Sciences (TWAS) in Trieste, Italy. He was bestowed with the D. M. Trivedi Lifetime Achievement Award of Indian Chemical Council as well as the Dr. B. P. Godrej Lifetime Achievement Award of the Indian Institute of Chemical Engineers (IIChE). The Indian Speciality Chemical Manufacturers Association (ISCMA) and PSN College of Engineering TN have bestowed the Best Researcher award for 2012. Three Rotary Clubs in Mumbai have bestowed on him excellence in vocation awards.